|
|
|
|
Glioma News Headlines
|
|
|
|
|
|
|
All Recent Glioma News Headlines |
|
|
|
|
MRP3: a molecular target for human glioblastoma multiforme immunotherapy
Conclusions:
Human GBMs overexpress MRP3 at both mRNA and protein levels, and elevated MRP3 mRNA levels in GBM biopsy samples correlated with a higher risk of death. These data suggest that the tumor-associated antigen MRP3 has potential use for prognosis and as a target for malignant glioma immunotherapy. (Source: BMC Cancer)...
POSTED 08/31/2010 at 06:00 PM --
|
Inositol-requiring enzyme 1{alpha} is a key regulator of angiogenesis and invasion in malignant glioma [Medical_Sciences]
Inositol-requiring enzyme 1 (IRE1) is a proximal endoplasmic reticulum (ER) stress sensor and a central mediator of the unfolded protein... (Source: Proceedings of the National Academy of Sciences)...
POSTED 08/31/2010 at 02:17 PM --
|
{alpha}2,3-Sialylation regulates the stability of stem cell marker CD133
CD133 is widely used as a marker for the isolation and characterization of normal and cancer stem cells. The dynamic alternation of CD133 glycosylation contributes to the isolation of normal and cancer stem cells, and is supposed to be associated with cell differentiation. Although CD133 has been identified as a N-glycosylated protein, the specific glycosylation status of CD133 remain unclear. Here, we found that CD133 could be sialylated in neural stem cells and glioma-initiating cells, and the sialyl residues attach to CD133 N-glycan terminal via 2,3-linkage. Furthermore, desialylation of CD133 by neuraminidase specifically accelerates its degradation in lysosomes-dependent pathway. Taken together, our results characterized CD133 as an 2,3-sialylated glycoprotein and revealed that the si......
POSTED 08/30/2010 at 09:41 AM --
|
Dissection of mitogenic and neurodegenerative actions of cystine and glutamate in malignant gliomas
Authors: N E Savaskan, S Seufert, J Hauke, C Tränkle, I Y Eyüpoglu
& E Hahnen (Source: Oncogene)...
POSTED 08/29/2010 at 06:00 PM --
|
Accumulation o f CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation.
(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)...
POSTED 08/29/2010 at 11:12 AM --
|
Accumulation o f CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation.
(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)...
POSTED 08/29/2010 at 11:12 AM --
|
Metabolism and regional cerebral blood volume in autoimmune inflammatory demyelinating lesions mimicking malignant gliomas
Abstract Dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) and MR spectroscopy are thought to differentiate tumefactive
autoimmune inflammatory demyelinating lesions from glial brain tumours. The aim of this work is to evaluate whether regional
cerebral blood volume (rCBV), as well as choline (Cho), N-acetyl-aspartate (NAA) and myo-inositol (mIns) concentrations differ between tumefactive lesions and World Health Organization
(WHO) grade IIâIII gliomas. Five patients with single autoimmune inflammatory demyelinating lesions and nine patients with
WHO grade II and III gliomas were examined by DSC-MRI and by two-dimensional (2D) 1H MR spectroscopic imaging (1H-MRSI). rCBV values and metabolite concentrations were normalised to the respective va......
POSTED 08/28/2010 at 12:55 AM --
|
Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia
This study confirms that the majority of patients with high potassium channel antibodies have limbic encephalitis without tumours. The identification of leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 as the major targets of potassium channel antibodies, and their associations with different clinical features, begins to explain the diversity of these syndromes; furthermore, detection of contactin-associated protein-2 antibodies should help identify the risk of an underlying tumour and a poor prognosis in future patients. (Source: Brain)...
POSTED 08/27/2010 at 08:47 PM --
|
Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide
We present the case of a 26-year-old male suffering a fatal ICH in the context of treatment of a high grade glioma with temozolomide. The clinician should be aware that a dose dependent severe and possible irreversible myelotoxicity can occur with temozolomide treatment resulting in substantial morbidity. (Source: Clinical Neurology and Neurosurgery)...
POSTED 08/27/2010 at 04:30 AM --
|
The combination of neuronavigation with transcranial magnetic stimulation for treatment of opercular gliomas of the dominant brain hemisphere
Conclusion: This method is useful for preoperative localization of the speech area, as well as preoperative planning of the operative approach and intra-operative planning of the direction of brain retraction and operative corridor. (Source: Clinical Neurology and Neurosurgery)...
POSTED 08/27/2010 at 04:30 AM --
|
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide
Conclusion: Temozolomide can cause early radiation induced injury which can mimic progressive tumor. Although the discrimination between two entities results in the accurate evaluation of response to therapy and benefits those patients, it did not affect overall survival. MRI spectroscopy is a valuable tool to define early radiation necrosis and should be further evaluated in larger prospective studies. (Source: Clinical Neurology and Neurosurgery)...
POSTED 08/27/2010 at 04:30 AM --
|
Elevated peritumoural rCBV values as a mean to differentiate metastases from high-grade gliomas
Conclusions The rCBV in the peritumoural area of contrast-enhancing brain tumours has a high diagnostic accuracy to discriminate metastases
from GBM irrespective of surrounding oedema and without the bias of slice selection and ROI positioning. Metastases should
be excluded, if at least one tumour-depicting slice reveals an increase of peritumoural rCBV compared to the normal contralateral
brain (normalised rCBV value >1). Conversely, the decrease of peritumoural rCBV may not reliably exclude GBM.
Content Type Journal ArticleDOI 10.1007/s00701-010-0774-7Authors
Stella Blasel, Institute of Neuroradiology, University of Frankfurt, Schleusenweg 2-16, Frankfurt, 60528 GermanyAlina Jurcoane, Institute of Neuroradiology, University of Frankfurt, Schleusenweg 2-16, Fra......
POSTED 08/27/2010 at 01:17 AM --
|
Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas
Abstract Anti-angiogenic agents targeting brain tumor neovasculature may increase progression-free survival in patients with recurrent
malignant gliomas. However, when these patients do recur it is not always apparent as an increase in enhancing tumor volume
on MRI, which has been the standard of practice for following patients with brain tumors. Therefore alternative methods are
needed to evaluate patients treated with these novel therapies. Furthermore, a method that can also provide useful information
for the evaluation of conventional therapies would provide an important advantage for general applicability. Diffusion-weighted
magnetic resonance imaging (DWI) has the potential to serve as a valuable biomarker for these purposes. In the current study,
we explore the prog......
POSTED 08/26/2010 at 01:13 PM --
|
Papillary endothelial hyperplasia presenting as recurrent malignant glioma
In this report, we provide a comprehensive review of this rare entity and emphasize the importance
of adequately pursuing appropriate diagnostic considerations prior to making definitive treatment decisions.
Content Type Journal ArticleDOI 10.1007/s11060-010-0338-yAuthors
Shirley S. Ong, Department of Neuro-oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston, TX 77030, USAJanet Bruner, Department of Neuropathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 USADawid Schellingerhout, Department of Neuroradiology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030 USAVinay K. Puduvalli, Department of Neuro-oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston, TX 7......
POSTED 08/26/2010 at 03:11 AM --
|
Effect of vascular endothelial growth factor on remodeling of C6 glioma tissue in vivo
This study was a comprehensive investigation
of the effects of VEGF on remodeling of glioma tissue in vivo. C6 cells with expression vectors containing sense (C6/VEGF+)
or antisense (C6/VEGFâ) VEGF164 complementary DNA (cDNA) or an empty vector (C6/vec) were implanted into athymic mice, which served as an in vivo model with
different levels of VEGF expression. VEGF expression, water content, and morphological characteristics of these tumor tissues
were assayed. Expression of VEGF and water content in C6/VEGFâ glioma (C6/VEGFâG) tissues were lower than in C6, C6/VEGF+,
and C6/vec glioma (C6G, C6/VEGF+G, C6/vecG) (P < 0.01, P < 0.05); water content correlated with VEGF expression (r = 0.791, P = 0.000). In C6/VEGFâG, tumor ......
POSTED 08/26/2010 at 03:11 AM --
|
Cerebellar glioblastoma multiforme with non-contiguous grade 2 astrocytoma of the temporal lobe in the same individual
We report a unique occurrence of such a combination in a 50-year-old man who presented with features of elevated intracranial pressure, ataxia and vertigo. Magnetic resonance imaging showed a diffuse non-enhancing lesion in the temporal lobe and insula and another non-contigous well defined enhancing lesion in the cerebellum. Both the lesions had mass effect. The lesions were decompressed; first the temporal lesion and then the cerebellar lesion. Histopathology revealed grade II astrocytoma in the temporal lobe and glioblastoma multiforme in the cerebellum. He recieved whole brain radiotherapy with which he showed symptomatic improvement and survived for 1.5 years. (Source: Neurology India)...
POSTED 08/25/2010 at 01:51 AM --
|
Immune therapeutic targeting of glioma cancer stem cells
Abstract Glioblastoma multiforme (GBM) is a lethal cancer that responds poorly to radiotherapy and chemotherapy. Glioma cancer stem
cells (gCSCs) have been shown to recapitulate the characteristic features of GBM and to mediate chemotherapy and radiation
resistance. Immunotherapeutic targeting of this cell population holds therapeutic promise but must be considered in the context
of the immunosuppressive properties mediated by the gCSC. Recent findings have indicated that this goal will be challenging
because the gCSC can suppress both the innate and adaptive immune systems by a variety of gCSC-secreted products and cell-membrane
interactions. In this review article, we will attempt to reconcile the disparate research findings regarding the potential
of immune targeting of......
POSTED 08/24/2010 at 12:10 PM --
|
Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas
Conclusions. Primary glioblastomas could be sub-classified according to the properties of their CD133+ cells. The molecular characterization of these potential stem cell populations could be critical to find new therapeutic targets and to develop an effective therapy for these tumours with very dismal prognosis. (Source: BMC Cancer)...
POSTED 08/23/2010 at 06:00 PM --
|
[Reirradiation in primary or secondary brain tumors.]
Authors: Noël G, Mazeron JJ
The purpose of this review was to analyze data available on reirradiation for high-grade glioma or brain metastasis. This reirradiation can be 3D conformal or stereotactic. There are no randomized trials. No definitive recommendations can be given but solutions can be proposed. In high-grade gliomas, results of 3D conformal irradiation are fair. Stereotactic irradiation produces more encouraging survival rates but the range of doses delivered is too large for allowing recommendations. However, fractions less than 5Gy seem better tolerated. In brain metastases, total brain irradiation seems useful if metastases are multiple and the patient in good condition. With radiosurgery, local control rates are high and survival encouraging. In a retrospective study,......
POSTED 08/23/2010 at 06:00 PM --
|
Epilepsy is related to theta band brain connectivity and network topology in brain tumor patients
Conclusions:
These results indicate that (pathologically) increased theta band connectivity is related to a higher number of epileptic seizures in brain tumor patients, suggesting that theta band connectivity changes are a hallmark of tumor-related epilepsy. Furthermore, a more random brain network topology is related to greater vulnerability to seizures. Thus, functional connectivity and brain network architecture may prove to be important parameters of tumor-related epilepsy. (Source: BMC Neuroscience - Latest articles)...
POSTED 08/22/2010 at 06:00 PM --
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE:
The information provided on this site is intended for your general knowledge only and is not a substitute for professional
medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a
qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.
|
|
|
|
|
|
|
|
Featured Product! |
 |
|
Arthrit-Eze |
|
Arthrit-Eze is the most advanced
formula on the market today |
|
It offers potential relief and
rejuvenation for all forms of arthritis, safely, naturally and without side
effects!
NO PRESCRIPTION REQUIRED! |
|
CLICK HERE
for more info... |
|
|
